Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer

M. Z. Berger, M. G. Kris, Richard J. Gralla, L. D. Marks, L. M. Potanovich, J. J. Dimaggio, R. T. Heelan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)124-126
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

amonafide
Non-Small Cell Lung Carcinoma
Intercalating Agents
Phlebitis
Leukopenia
Exanthema
Thrombocytopenia
Antineoplastic Agents
Nausea
Vomiting
Appointments and Schedules
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Berger, M. Z., Kris, M. G., Gralla, R. J., Marks, L. D., Potanovich, L. M., Dimaggio, J. J., & Heelan, R. T. (1991). Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 14(2), 124-126.

Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. / Berger, M. Z.; Kris, M. G.; Gralla, Richard J.; Marks, L. D.; Potanovich, L. M.; Dimaggio, J. J.; Heelan, R. T.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 14, No. 2, 1991, p. 124-126.

Research output: Contribution to journalArticle

Berger, MZ, Kris, MG, Gralla, RJ, Marks, LD, Potanovich, LM, Dimaggio, JJ & Heelan, RT 1991, 'Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 14, no. 2, pp. 124-126.
Berger, M. Z. ; Kris, M. G. ; Gralla, Richard J. ; Marks, L. D. ; Potanovich, L. M. ; Dimaggio, J. J. ; Heelan, R. T. / Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1991 ; Vol. 14, No. 2. pp. 124-126.
@article{1497e8c79afd41e285efc5724fe61cb0,
title = "Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer",
abstract = "Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95{\%} confidence limits 0-20{\%}). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44{\%}), nausea or vomiting (38{\%}), and thrombocytopenia and rash (each 25{\%}) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.",
author = "Berger, {M. Z.} and Kris, {M. G.} and Gralla, {Richard J.} and Marks, {L. D.} and Potanovich, {L. M.} and Dimaggio, {J. J.} and Heelan, {R. T.}",
year = "1991",
language = "English (US)",
volume = "14",
pages = "124--126",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer

AU - Berger, M. Z.

AU - Kris, M. G.

AU - Gralla, Richard J.

AU - Marks, L. D.

AU - Potanovich, L. M.

AU - Dimaggio, J. J.

AU - Heelan, R. T.

PY - 1991

Y1 - 1991

N2 - Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

AB - Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025805839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025805839&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 124

EP - 126

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -